Arrowhead Pharmaceuticals
Develops targeted RNAi medicines and markets REDEMPLO for familial chylomicronemia syndrome.
Something off on this page? Send us feedback.
Profile
Develops RNA interference medicines with its TRiM platform and sells REDEMPLO for familial chylomicronemia syndrome. Revenue combines product sales with licensing, milestones and royalties from partnered programs, while wholly owned candidates span cardiometabolic, obesity, pulmonary and central nervous system targets.
Develops and commercializes RNA interference medicines using TRiM, a ligand-mediated platform designed to deliver small interfering RNA to specific cell types. REDEMPLO (plozasiran), its first commercial product, treats familial chylomicronemia syndrome and is approved in the United States, Canada, China, Australia and the European Union; Sanofi holds Greater China rights.
Advances wholly owned programs including plozasiran for severe hypertriglyceridemia, zodasiran for inherited high cholesterol, ARO-INHBE and ARO-ALK7 for obesity, ARO-RAGE for pulmonary disease and ARO-MAPT for neurological disease. Its portfolio also includes candidates licensed to Sarepta, Amgen, Takeda, GSK, Novartis and Madrigal.
Combines discovery, clinical development, commercialization and growing in-house oligonucleotide manufacturing. Product sales coexist with collaboration payments and royalties, while trial outcomes, regulatory approvals and partners' development decisions govern much of the pipeline's economics.
Company facts
Key statistics
Year to date +25.3% · Average volume (30d) 1.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | H.C. Wainwright | Target | $115 | $120 | ||
| Aug 5, 2026 | Stifel Nicolaus | Target | $98 | $104 | ||
| Jul 27, 2026 | H.C. Wainwright | Target | $100 | $115 | ||
| Jul 23, 2026 | Morgan Stanley | Reiterate | Overweight | $100 | $120 | |
| Jul 23, 2026 | Piper Sandler | Reiterate | Overweight | $110 | $126 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q3 FY26 | −$1.28 | −$1.36 | −6.3% | $44.2M | $75.3M | +70.4% | −2.99% |
| May 7, 2026Q2 FY26 | −$1.18 | −$0.93 | +21.2% | $73.8M | $73.7M | −0.1% | −6.75% |
| Feb 5, 2026Q1 FY26 | $0.60 | $0.22 | −63.3% | $213.9M | $264.0M | +23.4% | −0.19% |
| Nov 25, 2025Q4 FY25 | −$0.11 | −$0.18 | −61.3% | $175.3M | $256.5M | +46.3% | +23.34% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $542.7M | $27.8M | $256.5M | $264.0M | $73.7M | $75.3M | |
| Gross profit | $542.7M | $27.8M | $256.5M | $264.0M | $73.7M | $75.3M | |
| Operating income | $381.2M | −$165.6M | $44.1M | $40.8M | −$141.3M | −$170.1M | |
| Net income | $370.4M | −$175.2M | −$23.8M | $30.8M | −$132.7M | −$194.3M | |
| Diluted EPS | $2.75 | −$1.26 | −$0.17 | $0.22 | −$0.93 | −$1.36 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Operating margin | 70.2% | -596.2% | 17.2% | 15.5% | -191.6% | -226.0% |
Fiscal years (4-quarter sums)FY21 $138.3M · FY22 $243.2M · FY23 $240.7M · FY24 $3.6M · FY25 $829.4M
Balance sheet, Jun 30, 2026Cash & short-term investments $1.60B · Total debt $864.1M · Total assets $2.11B · Shareholders' equity $465.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 140.86M · Float 122.78M · 87.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.83M | 10.53% | 13F | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 11.36M | 8.06% | 13F | Aug 14, 2026 |
| FMR LLC | 8.04M | 5.71% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 6.35M | 4.51% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.11M | 4.34% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Adeoye Y. Olukotun | director | −2,000 | $86.96 |
| Aug 18, 2026 | Michael S. Perry | director | −11,600 | $87.30 |
| May 12, 2026 | Hongbo Lu | director | −2,970 | $76.88 |
| Apr 23, 2026 | James C. Hamilton | officer: Chief Medical Officer | −10,000 | $75.00 |
| Apr 22, 2026 | Daniel Joseph Apel | officer: Chief Financial Officer | −13,095 | $71.35 |
Peers
- Alnylam Pharmaceuticals
The dominant commercial RNAi pure-play with six approved medicines.
- Ionis Pharmaceuticals
Direct FCS/sHTG commercial rival with an active patent suit against plozasiran.
- Novartis (ADR)
Global pharma with the leading Phase 3 DM1 RNA program via Avidity acquisition.
- Wave Life Sciences
Multi-modal RNA medicines peer; direct AATD overlap with fazirsiran.
- Silence Therapeutics (ADR)
UK-based GalNAc-siRNA liver platform; Phase 3-ready Lp(a) and ANGPTL3 programs.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | $84.80 | −0.13% | $11.96B | — | — | 17.9 | +171.0% |
| Alnylam Pharmaceuticals | $240.00 | +1.22% | $31.73B | 40.1 | 26.7 | 6.6 | +66.9% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Wave Life Sciences | $5.09 | +1.07% | $993.1M | — | — | 15.2 | −73.9% |
| Silence Therapeutics (ADR) | $13.42 | −0.30% | $633.9M | — | — | 1,031.9 | −38.8% |
| Median | 31.6 | 21.5 | 11.6 | −38.8% |